Updates are available Correction dated 2026-02-24
Click to view Correction: https://doi.org/10.1186/s12931-026-03576-8
-
Authors
Wilgus, May-Lin
Edmonds, Andrew
Keller, Kayleigh P.
Elf, Jessica L.
Abraham, Alison G.
Bhatt, Surya P.
Buhr, Russell G.
Cohen, Mardge H.
Detels, Roger
Drummond, M. Bradley
Fischl, Margaret A.
Foronjy, Robert
Hosgood, H. Dean
Huang, Laurence
Kunisaki, Ken M.
McCormack, Meredith
Morris, Alison
Raju, Sarath
Ramirez, Catalina
Rudolph, Jacqueline
Stosor, Valentina
Tashkin, Donald P.
Visconti, Adam
Weiser, Sheri D.
Wingood, Gina
Barjaktarevic, Igor
- License Information
-
More Information
Article History
Received: 23 June 2025
Accepted: 17 October 2025
First Online: 19 December 2025
Change Date: 26 February 2026
Change Type: Update
Change Details: The original online version of this article was revised: The co-author name has been corrected.
Change Date: 24 February 2026
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12931-026-03576-8
Declarations
:
: Research was conducted in accordance with the Declaration of Helsinki. All MACS and WIHS participants consented to cohort participation and use of their data for research, with approval obtained from relevant institutional review boards.
: Not applicable.
: SB: Funding from NIH, Nuvaira, Sanofi/Regeneron, Genentech. Fees from Sanofi, Regeneron, Boehringer Ingelheim, Apreo, Genentech, Chiesi, AstraZeneca, GSK, Merck, Verona Pharma, Polarean, Integrity CE, Medscape, Horizon CME, Illuminate Health, Integratias Communications.RGB: Funding from NIH/NHLBI, University of California Office of the President, NIH/NCATS, VA/HSR&D, COPD Foundation, and Foundation of the NIH. Fees from DynaMed/American College of Physicians, 2ndMD, Chiesi, Optum, Pri-Med.KMK: Fees from Nuvaira.AM: Funding from Pfizer.SR: Funding from NIH and Areteia Therapeutics.DT: Funding from NIH/NHLBI, Foundation of the NIH, and COPD Foundation.IB: Funding from Theravance and Viatris, Aerogen, Alpha-1 Foundation, Johnny Carson’s Foundation, Takeda, Amgen. Fees from AstraZeneca, Sanofi/Regeneron, Grifols, Verona Pharma, Inhibrx, Takeda, Genentech, Aerogen, Therevance and Viatris.
